Printer Friendly

Two Ebola Patients Who Received Experimental Tx Have Recovered; Both patients received a treatment called mAb114, the first of five experimental treatments approved.

MONDAY, Aug. 27, 2018 (HealthDay News) -- Two of the first 10 people to receive an experimental Ebola treatment have recovered from the highly dangerous disease, Congo's health ministry says.

The patients received a treatment called mAb114, which was isolated from a survivor of an Ebola outbreak in 1995. It was the first of five experimental treatments Congo approved for use in a new outbreak that was declared on Aug. 1, the Associated Press reported. The other experimental treatments are ZMapp, Remdesivir, Favipiravir, and Regn3450 - 3471 - 3479. More than 3,400 people have received an experimental Ebola vaccine in this outbreak.

On Saturday, the head of the World Health Organization praised Congo officials for making the experimental treatments available, calling it "a global first, and a ray of hope for people with the disease," the AP reported.

To date, there have been 79 confirmed cases in the outbreak, including 42 deaths and 14 patients who have recovered. There are another 28 probable cases. This is Congo's tenth Ebola outbreak. The disease can be fatal in up to 90 percent of cases, depending on the strain.

AP News Article More Information

COPYRIGHT 2018 HealthDay
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Physician's Briefings
Geographic Code:6ZAIR
Date:Aug 27, 2018
Words:189
Previous Article:Pediatricians Advise Against Use of Marijuana in Pregnancy; Concerns relate to short-term growth, long-term neurodevelopmental consequences of...
Next Article:Most Research Participants Not Concerned About Data Sharing; 93 percent very or somewhat likely to allow their data to be shared with university...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters